"New Study on ‘Breakthrough’ Atopic Dermatitis Drug Indicates ‘Eczema Is An Autoimmune Disease’"
Researchers behind a new study on the atopic dermatitis drug “dupilumab” (which is currently in trials) say that they have proven that this form of eczema is an autoimmune disease. The potential atopic dermatitis medication blocks the activity of two key immune proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), and according to the researchers, can reverse the immune response within an allergic individual that causes the atopic dermatitis skin problems. The promising new atopic dermatitis drug study was led by Emma Guttman-Yassky, MD, Associate Professor of Dermatology at the Icahn School of Medicine at Mount Sinai. Learn more.
Combination Therapy Improves Outcomes for Advanced Triple-Negative Breast Cancer
Aug 21, 2025 View All Press Releases
AI Could Help Emergency Rooms Predict Admissions, Driving More Timely, Effective Care
Aug 11, 2025 View All Press Releases
“Forever Chemicals” Linked to Higher Risk of Type 2 Diabetes
Jul 22, 2025 View All Press Releases
Like Humans, AI Can Jump to Conclusions, Mount Sinai Study Finds
Jul 22, 2025 View All Press Releases
Mount Sinai Researchers Engineer Rare Immune Cells to Create Powerful New Cancer Vaccine
Jul 21, 2025 View All Press Releases